Ivim Health Compounded GLP-1 review: is it worth it?

What is Ivim Health and how does it work?

Ivim Health (legal entity IVIM Services LLC) is a telehealth company founded in 2021 and headquartered in Columbus, Ohio. It was founded by Dr. Taylor Kantor along with family members, and it markets itself around cardiometabolic and weight-management care, also offering a separate hormone-replacement-therapy program. The company says it operates across all 50 states through a network of licensed providers — including obesity-medicine clinicians and nurse practitioners — and markets a large patient base. (Patient and provider counts are company marketing figures and are not independently verifiable.)

The process is the standard async-plus-video telehealth flow:

1. Intake questionnaire. You complete an online health history covering weight, conditions, medications, and goals.
2. Provider review. A licensed clinician reviews your information (and, depending on state rules, may require a video visit) to determine whether a GLP-1 is appropriate and which one.
3. Prescription and fulfillment. If approved, the prescription is routed either to a compounding pharmacy (for compounded semaglutide/tirzepatide) or, where you choose it, toward brand-name medication.
4. Ongoing membership care. Your $75/month membership funds follow-up video visits, dose titration, messaging support, and coaching for as long as you stay enrolled.

It is important to be precise here: Ivim is a *prescribing and coordination service*, not a manufacturer. The actual medication is made by third-party pharmacies, and the actual drug molecules (semaglutide, tirzepatide) are the same active ingredients found in Wegovy, Ozempic, Zepbound, and Mounjaro. What Ivim sells is access — clinical evaluation, a prescription, and a supply chain — not a proprietary product. This distinction is not academic: the FDA's February 2026 warning letter to Ivim cited the company for displaying compounded products labeled "Ivim" in a way the agency said could create the false impression that Ivim manufactures the drugs (see the regulatory section below).

What does Ivim Health cost and what do you actually pay?

There are two cost components, and conflating them is the most common mistake buyers make.

1. Membership. The Ivim membership is $75/month (listed as $74.99), often with the first month included or free in an initial bundle. This is a recurring charge that continues for as long as you want clinical oversight and refills.

2. Medication. Compounded medication is billed separately, frequently in multi-month blocks. Publicly listed pricing on Ivim's site has started around $75/month for compounded semaglutide and $149/month for compounded tirzepatide, on top of the program fee, with multi-month prepay plans available:

• Compounded semaglutide: roughly $499 for a 4-month plan and around $600 for a 6-month plan — which works out to about $75–$125 per month for the drug depending on the term and any promotions.
• Compounded tirzepatide: roughly $900 for a 4-month plan and around $1,100 for a 6-month plan — roughly $133–$225 per month.

Longer prepaid commitments lower the per-month price. Klarna installment financing is offered. (Prices change frequently; confirm current figures on Ivim's pricing page before committing.)

The realistic all-in number: add the medication block to the $75/month membership. A semaglutide patient on a 4-month plan is looking at roughly $175–$200/month all-in in the early months; a tirzepatide patient meaningfully more. Brand-name Wegovy or Zepbound through Ivim costs substantially more — typically several hundred dollars per month — and is gated by what the manufacturer cash programs and your eligibility allow.

On insurance and taxes: Ivim operates as a direct-pay service and does not bill insurance for the program itself. It will, on request, submit prior-authorization paperwork to see whether your plan will cover brand-name medication separately. Memberships and medications are generally HSA/FSA-eligible, which is a genuine and often-overlooked way to reduce the effective cost.

Is compounded medication through Ivim legitimate and safe?

This is where an honest review has to slow down, because the regulatory picture changed dramatically and most older reviews are out of date.

The shortage is over, and that matters legally. Compounded GLP-1s exploded in 2023–2024 under a specific legal allowance: when an FDA-approved drug is in official shortage, pharmacies may compound copies. The FDA determined the tirzepatide shortage resolved on October 2, 2024, and confirmed it in a formal Declaratory Order on December 19, 2024, and declared the semaglutide shortage resolved on February 21, 2025 (FDA). With the shortages gone, the broad enforcement-discretion window that made mass compounding legal closed: the FDA set wind-down deadlines (503A pharmacies and 503B outsourcing facilities had to stop compounding copies once their respective enforcement periods lapsed in early-to-mid 2025). In 2025–2026 the FDA went further, proposing to formally exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list after finding no clinical need for outsourcing facilities to compound them from bulk substances (FDA). Courts declined to grant preliminary injunctions blocking the agency's shortage-resolution decisions (Outsourcing Facilities Association v. FDA, N.D. Tex., preliminary injunction denied April 2025).

Ivim itself drew FDA scrutiny in 2026. On February 20, 2026, the FDA issued a warning letter to IVIM Services LLC (dba Ivim) — one of roughly two dozen warning letters the agency sent to GLP-1 marketers in a single day. The letter focused on misbranding: the FDA said the compounded products pictured on Ivim's website carried "Ivim" labeling that could falsely imply Ivim manufactures them, when in fact external pharmacies do. The agency's concern in the letter was about how the products are *marketed and labeled*, not a finding that the medication itself is unsafe — but a warning letter is a serious compliance signal and a reason to scrutinize any marketing claims carefully.

What's left is a narrow lane. Compounding can still be lawful for a documented, *individualized* clinical need that the commercial product can't meet — for example, a true allergy to an inactive ingredient in the branded pen, or a specific concentration not commercially available. A compounded version that is essentially "just a cheaper copy" of Wegovy or Zepbound is no longer in a comfortable safe harbor. Any program still offering compounded GLP-1s broadly should be selling them on the basis of personalization, and you should understand that the legal and supply footing is far less stable than it was a year ago.

Compounded drugs are not FDA-approved. This is not a slogan; it is the central caveat. As the FDA states, compounded drugs are not FDA-approved and the agency does not review them for safety, effectiveness, or quality before they reach patients. They are made batch-by-batch by individual pharmacies.

The real-world safety signal is non-trivial. The FDA's adverse-event reporting system (FAERS) has logged hundreds of reports tied to compounded semaglutide and tirzepatide — more than 900 combined cases, including 17 deaths, as of late 2024, according to FAERS data — and the agency issued a specific alert about dosing errors with compounded injectable semaglutide (FDA, 2024). In the majority of those reports, patients said they mistakenly drew 5 to 20 times the prescribed dose, with confusion between milligrams, milliliters, and "units"; the agency linked these errors to adverse events including hospitalization. The FDA has also warned about counterfeit products and salt-form versions of the molecule (e.g., "semaglutide sodium," "semaglutide acetate") that "have not been shown to be safe and effective" and are different active ingredients than the base form used in approved drugs (FDA). None of this is specific to Ivim, but it is the category Ivim operates in, and it is why dosing must be carefully controlled.

Where Ivim looks responsible: the company states it uses state-licensed compounding pharmacies, prescribes through licensed clinicians, and provides titration support — all of which reduce, though do not eliminate, the category-level risks above. It carries BBB accreditation (A+) and a Trustpilot score around 4.0/5 across tens of thousands of reviews, with the polarized distribution typical of telehealth: a large satisfied majority and a vocal minority citing cost, customer-service delays, and shipping problems.

How well do these medications actually work?

The encouraging news is that the *drugs themselves* — semaglutide and tirzepatide — are among the most effective weight-loss medications ever studied, and that evidence comes from large, peer-reviewed trials of the FDA-approved versions.

• Semaglutide 2.4 mg (the Wegovy molecule): In the pivotal STEP 1 trial, adults without diabetes lost an average of about 14.9% of body weight over 68 weeks, versus roughly 2.4% on placebo, with the majority of participants losing at least 5–10% (NEJM 2021, STEP 1; *N Engl J Med* 384:989).
• Tirzepatide (the Zepbound/Mounjaro molecule): In the SURMOUNT-1 trial, adults lost an average of roughly 16.0% to 22.5% of body weight depending on dose (5, 10, and 15 mg) over 72 weeks (NEJM 2022, SURMOUNT-1; *N Engl J Med* 387:205).
• Head-to-head: In SURMOUNT-5, the first direct comparison, tirzepatide produced greater average weight loss than semaglutide (about 20.2% vs. 13.7%) over 72 weeks (NEJM 2025, SURMOUNT-5), making it the more potent option for many patients.

A crucial caveat for any compounded-program shopper: these percentages come from the FDA-approved, brand-name products at validated doses. Compounded preparations use the same active molecule, so the pharmacology should be similar, but the specific compounded formulation has not itself been tested for potency, purity, or equivalence in clinical trials. It is reasonable to expect compounded semaglutide or tirzepatide to work broadly like its branded counterpart when correctly dosed — but that is an inference, not proven equivalence, and dose accuracy is the variable most under threat in the compounded setting.

It's also worth stating what the trials show about durability: weight tends to return after stopping. In the STEP 4 withdrawal trial (JAMA 2021), participants switched to placebo regained about 7% of body weight over the following 48 weeks, while those who continued semaglutide kept losing. That makes the *ongoing* nature of a membership program clinically relevant — but also makes the recurring cost a long-term commitment, not a one-time purchase.

What are the side effects and who should be cautious?

The side-effect profile is driven by the drug class, not by Ivim. The most common effects are gastrointestinal: nausea, vomiting, diarrhea, constipation, and abdominal discomfort, usually worst during dose escalation and improving over time. Slow titration — which a good telehealth program should provide — exists largely to manage this.

More serious, label-level concerns for GLP-1 (and GIP/GLP-1) agonists include:

• Pancreatitis and gallbladder disease (gallstones, cholecystitis).
• A boxed warning on the branded products for thyroid C-cell tumors based on rodent data; these drugs are contraindicated in people with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) (FDA labels for Wegovy, Ozempic, Zepbound, and Mounjaro).
• Caution with diabetic retinopathy, severe gastrointestinal disease, and a history of eating disorders.
• Pregnancy and breastfeeding are exclusions.

A specific compounded-setting risk worth repeating: dosing error. With multi-dose vials and syringes rather than a fixed-dose auto-injector pen, the margin for human error is wider. If you use a compounded program, insist on clear, written dosing instructions and confirm the concentration and the exact volume per dose with your prescriber.

Who is Ivim Health best for — and who should skip it?

It may be a reasonable fit if you:

• Want clinician-supervised GLP-1 therapy and don't have affordable insurance coverage for brand-name Wegovy or Zepbound.
• Value ongoing membership support (titration, messaging, coaching) rather than a transactional one-off prescription.
• Understand and accept the trade-offs of compounded, non-FDA-approved medication and want to use HSA/FSA dollars.

You should probably skip it — or at least choose the brand-name route — if you:

• Can get Wegovy or Zepbound covered by insurance, or qualify for the manufacturers' own cash-pay programs (LillyDirect for Zepbound; the NovoCare self-pay channel for Wegovy), which now sell single-dose-vial brand product at prices that have narrowed the gap with compounding. As of early 2026, LillyDirect Zepbound vials run roughly $299–$449/month depending on dose and refill timing, and NovoCare Wegovy is about $349/month (with periodic lower introductory tiers).
• Have any contraindication above (thyroid history, pancreatitis history, pregnancy).
• Are uncomfortable self-measuring injections or want the regulatory certainty of an FDA-approved product.

How does Ivim compare to alternatives?

The telehealth GLP-1 space is crowded; Ivim sits in the mid-tier on price and reputation.

• Vs. manufacturer-direct (LillyDirect, NovoCare): These now offer brand-name, FDA-approved medication via self-pay, removing the compounding question entirely. They are usually more expensive per month than the cheapest compounded plans but eliminate the legal and quality uncertainty — increasingly the better default for many patients in 2026, especially as their cash prices have fallen.
• Vs. large telehealth platforms (Hims & Hers, Ro, Sesame, Henry Meds, etc.): These compete largely on price, app polish, and bundled support. Ivim's differentiators are its obesity-medicine clinician emphasis and membership model; its disadvantages are a membership fee layered on top of medication and mixed customer-service reviews. On raw price, several competitors undercut Ivim, especially on long prepaid semaglutide plans.
• Vs. a local doctor + insurance: If covered, this is almost always cheaper and gives you FDA-approved product, but it requires you to clear prior authorization and often a step-therapy gauntlet that telehealth conveniently bypasses.

The bottom line

Ivim Health is an established telehealth operation with licensed clinicians, transparent two-part pricing ($75/month membership plus separate medication cost), and access to two of the most effective weight-loss molecules in medicine. For someone without insurance coverage who wants supervised care and is comfortable with the trade-offs, it can be a credible option — and the HSA/FSA eligibility and Klarna financing genuinely lower the barrier.

But the value proposition that made Ivim and its peers compelling — cheap compounded copies of Wegovy and Zepbound — rests on a foundation the FDA has been actively dismantling since the shortages ended in late 2024 and early 2025. Compounded GLP-1s are not FDA-approved, carry a documented dosing-error and quality risk, now sit in a much narrower legal lane, and Ivim itself received an FDA warning letter in February 2026 over how it markets them. Meanwhile, manufacturer self-pay programs have made the FDA-approved originals more affordable than they were.

The honest read: if you choose Ivim, strongly consider the brand-name path through its platform, or treat compounded medication as a deliberate, informed trade-off rather than simply "the cheap version." Confirm your pharmacy's accreditation, demand precise dosing instructions, and price-check against LillyDirect, NovoCare, and the larger telehealth players before committing to a multi-month prepay. The medication can work remarkably well; the smart move is making sure the *delivery* of it is as safe and as legally durable as the science behind it.

*This review is for informational purposes and is not medical advice. GLP-1 medications are prescription drugs with serious potential risks; discuss your personal eligibility and the FDA-approved versus compounded options with a licensed clinician before starting.*